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Motives of contributing personal data for
health research: (non-)participation in a
Dutch biobank
R. Broekstra1,2* , E. L. M. Maeckelberghe3, J. L. Aris-Meijer1, R. P. Stolk1 and S. Otten2
Abstract
Background: Large-scale, centralized data repositories are playing a critical and unprecedented role in fostering
innovative health research, leading to new opportunities as well as dilemmas for the medical sciences. Uncovering
the reasons as to why citizens do or do not contribute to such repositories, for example, to population-based
biobanks, is therefore crucial. We investigated and compared the views of existing participants and non-participants
on contributing to large-scale, centralized health research data repositories with those of ex-participants regarding
the decision to end their participation. This comparison could yield new insights into motives of participation and
non-participation, in particular the behavioural change of withdrawal.
Methods: We conducted 36 in-depth interviews with ex-participants, participants, and non-participants of a three-
generation, population-based biobank in the Netherlands. The interviews focused on the respondents’ decision-
making processes relating to their participation in a large-scale, centralized repository for health research data.
Results: The decision of participants and non-participants to contribute to the biobank was motivated by a desire
to help others. Whereas participants perceived only benefits relating to their participation and were unconcerned
about potential risks, non-participants and ex-participants raised concerns about the threat of large-scale,
centralized public data repositories and public institutes, such as social exclusion or commercialization. Our analysis
of ex-participants’ perceptions suggests that intrapersonal characteristics, such as levels of trust in society,
participation conceived as a social norm, and basic societal values account for differences between participants and
non-participants.
Conclusions: Our findings indicate the fluidity of motives centring on helping others in decisions to participate in
large-scale, centralized health research data repositories. Efforts to improve participation should focus on enhancing
the trustworthiness of such data repositories and developing layered strategies for communication with participants
and with the public. Accordingly, personalized approaches for recruiting participants and transmitting information
along with appropriate regulatory frameworks are required, which have important implications for current data
management and informed consent procedures.
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Background
There is an increasing collection and transmission of per-
sonal data in society. Biobanks and other large-scale, cen-
tralized data repositories are a special form of data
collection, storage, and use of large volumes of diverse
personal data obtained from patients and citizens. Their
aim is to contribute to the development of research activ-
ities in medicine [1–3]. They constitute valuable resources
for healthcare professionals and facilitate innovations in
epidemiological, genetic, and public health research [2, 4].
These data repositories facilitate the efficient performance
of large-scale and continuous data analyses and enable re-
searchers and clinicians to generate individual tailored
clinical care [5–9]. Contributing personal data to biomed-
ical research must be voluntary [9–14].
There is widespread consensus among European re-
searchers that contributions of personal data by citizens
foster scientific development and are therefore com-
mendable [14]. Studies show that participants also share
this consensus. They are motivated to do good deeds by
helping researchers, patients, and doctors [2, 15–17]. A
lot of citizens nonetheless choose not to contribute per-
sonal data for medical scientific research purposes, since
percentages of unwilling citizens in representative sam-
ples range from 17 to 44% [18, 19]. This raises the ques-
tion why some individuals do (participants) and others
(non-participants) do not actively contribute their per-
sonal data to data repositories for medical scientific re-
search, such as population-based biobanks.
The current literature mentions two types of risk that
might explain the decision to participate or not in med-
ical scientific research [2, 15]. The first type are the fore-
seeable risks associated with repositories, such as
increasing loss of direct control over personal data, loss
of privacy, or data breaches. The second type includes
less foreseeable risks, for example the risk of unauthor-
ised re-identification with potentially harmful conse-
quences that is incurred as a result of linking different
data repositories for the conduct of new kinds of ana-
lyses [2, 17, 20]. This second type of risk is, in contrast
to the first, a risk that is rarely addressed in currently
used consent forms yet exists [2].
The two types of risk offer however insufficient ex-
planation why some participants, which we refer to as
ex-participants, withdraw during the data collection
process. Several studies have suggested that withdrawal
or other non-participation is motivated by perceptions
of the consequences of helping others. For example,
concerns regarding the commercialization of public re-
search that derogates social benefits intended for others
[21–23], risks of privacy violations following individual
and group data sharing [2, 19, 22, 24–34], or potential
discrimination [35]. More insight is needed in what fac-
tors drive this behavioural change. A comparison of the
experiences of ex-participants of a biobank and non-
participants with the views of participants could there-
fore yield insights into the reasons for participation,
non-participation, and, in particular, withdrawal.
Our aim is to understand how motives, values, and ex-
pectations can differ in participation and non-participation.
This understanding of underlying mechanisms could yield
insights on variance in ethical understandings of biobank
research, improvement of research data governance in bio-
banking, and effective strategies of participant recruitment
in biomedical research. In this qualitative study of ex-
participants, participants, and non-participants of a Dutch
population-based biobank, we investigated and compared
the views of participants on contributing data to the bio-
bank with those of non-participants and ex-participants
about why they chose not to participate and why they
ended their participation respectively.
Methods
Data collection
We conducted in-depth interviews with individuals who
were ex-participants, non-participants, or participants in
Lifelines, a Dutch population-based biobank, to explore the
motives underlying their participation and non-
participation in a centralized health research data system.
Lifelines is a multidisciplinary, prospective population-
based cohort study that entails a unique three-generational
design for examining the health and health-related behav-
iours of individuals living in the Northern Netherlands.
Lifelines encompasses a broad range of investigative proce-
dures used to assess the biomedical, sociodemographic, be-
havioural, physical, and psychological factors that
contribute to health and disease within the general popula-
tion, with a special focus on multi-morbidity and complex
genetics [36]. The recruitment of participants began in
2006 and continued up to 2013. Recent year, Lifelines
launched an initiative introducing innovative big data tech-
nologies that include, for example, providing research par-
ticipants with personalized feedback.
We applied a narrative interview approach with a tai-
lored topic guide that was partly derived from the DIPex
methodology that allowed for a discussion, clarification,
and verification of unanticipated themes [37, 38]. The
topic guide, as shown in Table 1, was developed in a re-
search project about research (non-)participation and big
data consisting of the current study and a qualitative study
about trust [35]. Six relevant themes relating to the mo-
tives, values, and expectations associated with participa-
tion and non-participation were identified in this topic
guide, based on the state of knowledge evidenced in the
scientific literature on (non-)participation in biobanks,
public goods, trust, and data sharing: (1) becoming a
(non-)participant; (2) objective aspects of participation
(e.g., participation overall, tasks, and feedback); (3)
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subjective aspects of participation (e.g., expectations of ac-
complishment and feelings of identification); (4) defini-
tions of and attitudes towards big data; (5) perceived
benefits and threats associated with big data; and (6) deci-
sions to provide personal data. The topics discussed in the
interviews were derived from these themes.
All of the interviews were conducted by a member of
the research team (RB), who is a trained and experienced
interviewer. Each interview covered all of the topics in-
cluded in the guide and lasted between 30 and 65min.
Data saturation was reached, when informational redun-
dancy was achieved in the interviews [39]. Current par-
ticipants of Lifelines were interviewed following their
regular visits to the Lifelines facility. Most of the inter-
views were held at the University Medical Center Gro-
ningen. All four ex-participants and eight out of fifteen
non-participants were interviewed at their homes on
their request. All respondents provided verbal informed
consent for their participation and the recording of the
interview. This consent is documented by recording on
video or writing. Apart from one interviewee, who only
consented to a written recording of the interview, the
remaining interviewees consented to audio recordings of
their interviews. All of the audio recordings were tran-
scribed by an independent professional organization.
These recordings were anonymized and stored at the
highly secured servers of the University Medical Center
Groningen. The access to these servers is only with per-
mission of the researchers and excludes access for staff
of Lifelines. The Medical Ethics Review Board of the
University Medical Center Groningen exempted this
study from the ethics review according to the Medical
Research Involving Human Subjects Act of the
Netherlands, as it did not involve collection of any
health-related data.
Recruitment of respondents and sampling
A maximum variation sampling strategy was applied to
recruit participants for the study [40]. Thus, we ensured
that the sample of selected interviewees was heteroge-
neous [41, 42]. Between August and September 2016, we
interviewed 36 individuals: 17 participants, four ex-
participants, and 15 non-participants in the Lifelines bio-
bank. We refer to these distinct groups throughout this
paper as ‘interviewees’ while distinguishing ‘participants’,
‘ex-participants’, and ‘non-participants’. Table 2 shows
the characteristics of all of the interviewees. Their aver-
age age was 45 years (ranging between 20 and 68 years)
and 17 out of the 36 interviewees were male.
We recruited individuals partly from the Lifelines bio-
bank. To ensure their privacy, Lifelines recruited partici-
pants and ex-participants of the biobank without the
researchers being aware of their identity. Ex-participants
who had terminated their participation in the few
months prior to the commencement of our study were
approached by phone, using a protocol created by the
researchers (RB and JA) during the final stage of Life-
lines’ established withdrawal procedure. Moreover, the
Lifelines biobank also invited non-participating partners
of participants who had contributed to the biobank. Ex-
Table 1 Interview topics and illustrative questions
Topic Example questions
Association with biobank How did you get involved?
Decision of (non-)participation What were your considerations?
Reality Was your experience as expected or not?
Future Will you participate in Lifelines or in another centralised large-scale research project in the
future?
Overall perception How is participation in Lifelines perceived in general?
Tasks How are the tasks related to participation in Lifelines perceived?
Feedback What do you think of the feedback on your data you (would) receive?
Outcome hoped for What motivates individuals to participate?
Benefits What are the benefits and opportunities relating to participation?
Disadvantages What are the risks and disadvantages relating to participation?
Definition What are centralised large-scale data repositories?
Attitudes towards large-scale centralised data
repositories
Are the public’s attitudes towards collection, linking and use of this data generally positive or
negative?
Benefits of large-scale centralised data repositories What are the benefits of collecting, linking and using data?
Risks posed by large-scale centralised data
repository
What risks are posed by the collection, linking and use of data?
Personal balance of benefits and threats From your personal perspective, how are these considerations balanced?
Societal balance of benefits and threats From a societal perspective, how are these considerations balanced?
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participants were the least willing to participate in our
study. Although 90 people were invited, only four
(4.44%) consented to participate. Reasons given for not
participating in our study were ‘no interest’, ‘not avail-
able’, and ‘done with participating’. The sample of ex-
participants was too small to enable generalization, but
yielded the in-depth information that we were seeking.
Non-participants were recruited through direct encoun-
ters with members of the public at the entrance of
Groningen’s central public library and by personal invi-
tation vis-à-vis various social networks as well as
through online and offline platforms.
Data analysis
We analysed every phrase in each of the 36 interview tran-
scripts within the context of the entire interview, and,
where appropriate, a code pertaining to its content was
generated or assigned. Codes could be applied multiple
Table 2 Respondents’ Characteristics
Respondent Sex Age Occupational Field Participation status
1 Female 65–70 Human resources Participant
2 Male 40–45 Transportation Non-participant
3 Female 60–65 Education Non-participant
4 Male 30–35 Legal and social work Participant
5 Male 50–55 Photography and architecture Ex-participant
6 Male 55–60 Municipality Non-participant
7 Female 35–40 Home maintenance Ex-participant
8 Male 25–30 Warehouse maintenance Participant
9 Female 55–60 Retail Participant
10 Male 30–35 Entrepreneur Participant
11 Male 20–25 Student Participant
12 Female 50–55 Law Participant
13 Male 25–30 Student Non-participant
14 Male 65–70 Mechanical engineering Participant
15 Male 55–60 Home maintenance Non-participant
16 Female 25–30 Publisher Non-participant
17 Female 45–50 Entrepreneurship Non-participant
18 Female 65–70 Retired Participant
19 Male 50–55 Management Participant
20 Female 25–30 Energy policy Non-participant
21 Female 35–40 Healthcare Participant
22 Female 50–55 Healthcare Participant
23 Female 25–30 Human resources Non-participant
24 Female 45–50 Education Participant
25 Male 40–45 Municipality Participant
26 Female 65–70 Farming Non-participant
27 Female 40–45 Librarian Ex-participant
28 Female 50–55 Social work Ex-participant
29 Female 35–40 Management Participant
30 Male 35–40 Engineering Non-participant
31 Male 55–60 Human resources Non-participant
32 Female 30–35 Home maintenance Non-participant
33 Male 40–45 Management Participant
34 Female 60–65 Retired Participant
35 Male 35–40 Business development Non-participant
36 Male 45–50 Entrepreneurship Non-participant
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times within each transcript, and phrases could comprise
multiple codes. Codes with related content were clustered
within groups that were subsequently thematically catego-
rized. An initial coding protocol containing a description of
the codes, groups, and themes was developed based on a close
reading of three transcripts. This coding protocol was evalu-
ated through an iterative process, whereby two or three re-
searchers cross-checked analyses of each of the transcripts.
Once a consensus regarding the content of the codes, groups,
and themes had been reached, the resulting coding protocol
was used for the remaining transcripts. Five researchers coded
the transcripts. Six random transcripts were coded by at least
three researchers. This procedure ensured agreement among
the researchers regarding the coding. Subsequently, one re-
searcher coded all of the remaining transcripts.
The results of the interviews were categorized accord-
ing to four themes. One of these themes, ‘perception of
big data’, that emerged from our topic guide was se-
lected because it was a focal theme during the interviews
prior to the analytical phase. The other themes did not
emerge directly from our topic guide but instead fea-
tured prominently in the interview data. This approach
can be considered as valid, as the adaptive theory for
qualitative research allows for the influence of theory on
research [43]. Transcripts were primarily analysed using
the computer-assisted qualitative data analysis package,
Atlas TI, version 8, to retrace and evaluate quotes along
with their codes, groups, and themes [44].
Results
We distinguished five themes relating to the motives,
values, and expectations of ex-participants, participants,
and non-participants in our dataset. The first three themes
pertained to views and motives regarding the initial or
current participation of ex-participants and participants.
The last two themes touched on the ex-participants’ views
and motives relating to their withdrawal and on non-
participants’ views.
Contribution to the public good: science, healthcare, and
society
Initially, most of the participants perceived their partici-
pation in Lifelines in terms of the donation of their time,
information, and data to a public good, namely health.
They believed that they were helping society by volun-
tarily investing time and effort, which they could also do
in other ways. They compared their contribution of per-
sonal data to Lifelines to a gift bequeathed to a charity
or to organ donation. For example, one participant (P33)
explained: ‘My role is not to conduct research but to
provide things [such as information, money, or data]’.
Ex-participants emphasized that the central motive for
their initial participation in Lifelines was their desire to
contribute to society. According to them, the purpose of
research was to ‘gain insights’ and to ‘create innovation
in society’. Therefore, in their view, participation would fa-
cilitate societal progress. An ex-participant (EP28) ex-
plained this as follows: ‘There was at that time no reason to
say “no”. It was about gaining collective insights into the
world; you need people and you need a research group’.
This perception of contributing to societal progress
was fostered through the awareness that Lifelines is a
prospective cohort and a large-scale, centralized data re-
pository. Ex-participants argued that the scale and length
of the Lifelines data collection was unique and could
thus provide new insights for medical sciences in the
long term. Their initial expectations were that the results
and implications of the research conducted using Life-
lines data would primarily benefit future generations.
These expectations were similar to those of the partici-
pants. Two participants explained this as follows:
I think I have little benefit, I don’t know. I think it’s
for the generation after me, for which I’m partici-
pating in now.. .. My parents participated in such
events for us, and so I am participating for the next
generation. (P22).
Research must be useful for society as a whole [so]
that we ultimately flourish or become less ill. .. so that
things get better; so that we leave it better than we
found it. It is that idealistic idea so to speak. (P1).
For the participants, the primary motive for participa-
tion was to contribute to science. Moreover, all of the
participants and ex-participants subscribed to the belief
that participation would or could facilitate scientific pro-
gress and specifically the progress of the medical sci-
ences. Participants as well as ex-participants explicitly
stated that they highly valued scientific research in gen-
eral. Participants were primarily interested in improving
health and medical knowledge because they prioritized
health as a profoundly important value. They perceived
their donations of personal data as contributions to
health-related research that was aimed at facilitating a
better understanding of the development and course of
illnesses. One participant (P22) expressed the view that
‘the medical sciences can’t stagnate, so you must cooper-
ate in order to help people to do research and make it
better.. .. That is what my aim is’.
Participation to help family members or friends
Similarly, a motive for participation mentioned by the
interviewees, especially ex-participants, was ‘helping
family or friends’, which was described as an investment
of time and effort to benefit the current generation of
family members or friends. They perceived this as an
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important motive influencing their decision to partici-
pate. An ex-participant (EP27) made the following
statement:
As I recall, I participated because a family member
participated too. It was probably my mother, but I
am not sure.. .. We spoke about the (Lifelines)
research on health and diseases at that time.
However, exactly how that went I don’t recall
because of the passage of time. I started participat-
ing after that conversation.
Several current Lifelines participants who were re-
cruited by their friends or family members considered
participation in the programme to be almost self-
evident, given the objective of Lifelines to follow the tra-
jectories of three generations. A participant (P18) ex-
plained this as follows:
Well, we have two daughters; one daughter took part
in it and so did her son. So, I thought, “then someone
from our generation will have to participate too”, so
that they will have someone of my generation and get
three generations in total. My husband didn’t want to
participate, so I joined.
Contributing to obtain individual benefits
The prospect of a ‘medical check-up’ was also a motivat-
ing factor for the contributions of ex-participants. Once
every 5 years, participants visit a Lifelines location,
where they provide blood samples and are subjected to
physical measurements (e.g., those relating to anthro-
pometry, electrocardiogram, and spirometry). After-
wards, some of these measurements are returned to the
participants. Interviewees perceived this feedback as a
free medical check-up that provided them with extra
health-related information. These same results also sent
to the general practitioner (GP) with a recommendation
on whether the GP should actively contact the partici-
pant to arrange further clinical investigations.
Although participants highly appreciated this sharing
of data, which they valued as a supplementary bonus to
their personal healthcare, most of them emphasized that
it was not the primary motive for their participation.
They valued some of the other individual benefits as
well, such as ‘acquiring knowledge in general’, ‘learning
about themselves’, and ‘the joy of gaining insights into
the scientific process’. Despite the fact that all of the par-
ticipants were informed that not all of the measured data
would be returned and that the collected data would not
be screened for diseases, they felt that the chances of
obtaining an early diagnosis of illness would increase
through their participation in the programme. They also
assumed that they were free of any illness if their GPs
did not recommend further investigations. One partici-
pant (P19) noted:
I do like it. Suppose I am not in good health; it is of
course out of self-interest as well, to find out at the
earliest possible stage. Look, normally if you don’t have
anything, then you don’t go to a doctor. Nevertheless,
here an EEG is done, your blood is measured, your
urine is measured, and other things are done. So if
there is something wrong. .. then hopefully you will
know at an early stage. So, that is also one of the
reasons for me [to participate].
A few participants thought that their own data could
prove useful if they were later to fall ill. Participation
would therefore enable them to keep records of their
personal health. For example, according to one partici-
pant (P11), ‘it is a sort of back up. We [my GP and I]
can look into the past, if I feel ill or have some symp-
toms. Perhaps I [my GP and I] can use it?’ Applying this
line of reasoning, some of the participants specifically
observed that their participation and procurement of
data could provide their offspring with extra health-
related information.
Not contributing to a public good
Prior to their withdrawal from the programme, ex-
participants considered the large-scale, centralized data reposi-
tory to be a public good. However, this positive perception
later changed to suspicion, as they felt that their personal data
would be sold or misused. The new perception was driven by
sceptical news items, negative perceptions of family members
and friends, or a negative experience during a research visit.
They mentioned that their concerns about the data repository
being used by insurance companies or by the government to
exclude people collectively and individually were among the
primary reasons why they withdrew from the Lifelines
programme. Another reason pertained to their belief that Life-
lines was a profit-oriented organization and, therefore, their
participation did not contribute to a public good.
Non-participants also considered the risk of collective
exclusion with Lifelines to be plausible. For example,
they noted the effect of personalized information on in-
surance premiums that could derogate a ‘social society’.
Some of the non-participants pointed to historical evi-
dence of the isolation and exclusion of social groups
resulting from the misuse of comparable repositories or
systems. One non-participant (NP36) specifically re-
ferred to the civilian administrative system that prevailed
in the Netherlands prior to and during World War II: ‘
… they used to register the religions of civilians. That is
not done any more for good reasons. These practices
originate from World War II and the [treatment of the]
Jews. Those [data] were used to trace them’.
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Similar to ex-participants, non-participants generally
thought that their participation in large-scale, centralized
data repositories could prompt a decrease in life oppor-
tunities for themselves and others through decisions on,
for example, mortgages or governmental support. One
non-participant (NP6) elaborated on this point as follows:
Well look, if it [the data] is linked to healthcare
insurance, they could potentially determine from
this information that this male or female has a risk
that is above average. Therefore, they may ask for a
higher premium or deny the individual insurance.
That is. .. I perceive it as a definite risk and threat if
such organizations are involved.
Differing from ex-participants, however, non-participants
ranked the type of research compiled for population-based
biobanks lower than other types of research in terms of its
importance. Several non-participants were not particularly
concerned about health research, showing considerably
more interest in topics relating to economics or energy-
related innovations. Although they saw some use for re-
search facilitated by Lifelines data, they did not feel that
contributing their personal data would be of much use, as a
non-participant (NP20) explained:
I don’t necessarily perceive it [as being] negative;
nor do I immediately think: “oh yes, I am going to
participate”. I think that it depends very much on. ..
as you explained it now, it [research participation]
doesn’t attract me. I don’t think: “oh yes I have to
participate, because I can be of use” or something
like that.
A lack of individual benefits
Ex-participants explained that one of the reasons for
their withdrawal was that they did not perceive their
participation as being useful in terms of procuring per-
sonal benefits that matched their expectations. They dis-
covered that participants could still become ill regardless
of their participation in Lifelines, indicating a lack of in-
dividual benefit of a ‘medical check-up’. Although non-
participants also considered potential individual benefits
such as a ‘medical check-up’ or gaining ‘part of the
profit’, they did not especially value or see the individual
benefits gained from participating in Lifelines. This lack
of benefits for themselves did not motivate them to par-
ticipate in the biobank. One non-participant (NP31) ex-
plained this as follows:
It must clearly matter in my view. For a multi-year re-
search project, one can claim that it is of use. Of course,
it is of some use. However, it is difficult to grasp how
long it will [continue to] be of use.. .. Of course, if so
much data is compared, your data will disappear in a
large dataset.. .. Then you get research results from
which you must filter out the personal implications. In
that sense, for the larger group, it is wonderful that
many people are participating. Nevertheless, at this
point, I am not interested in participating for this reason
[lack of individual benefit].
Whereas some participants and ex-participants
expressed the view that personal health experiences fea-
tured in their decision to participate in Lifelines, some of
the non-participants explicitly stated that they had not
had any immediate experiences relating to health issues
themselves or within their families. Therefore, they did
not perceive the active contribution of personal data as
being imperative. As one non-participant (NP23) ex-
plained, ‘I don’t know any people with chronic diseases.. ..
I need some personal benefit. I can imagine that with Life-
lines, you get knowledge about your own health and body.
So either that or I am helping someone within my circle’.
Moreover, non-participants mentioned that the burden
of investing time for each visit, and for the duration of
participation, and the effort expended in relation to the
complexity of the performed tasks were also motives for
their non-participation. Non-participants found it diffi-
cult to acquire an overview of these burdens or costs
and of the implications of participating in a population-
based biobank. Some of them were hesitant about par-
ticipating because they were apprehensive about making
a long-term commitment to such a project.
Discussion
In this study, we investigated and compared the views of
participants and non-participants on contributing to a
large-scale, centralized health research data repository
with the perceptions of ex-participants who decided to
end their participation. We explored the motives, values,
and expectations of ex-participants, participants, and non-
participants of a Dutch population-based biobank
encompassing three generations. Participants and non-
participants evidenced different perceptions on how they
could help others through the contribution of their per-
sonal data for biomedical research. Nevertheless, they
shared similar intentions about contributing to society
and science and helping family members and friends. Par-
ticipants and non-participants did not agree on realistic
risk levels relating to participation. Thus, non-participants
and ex-participants expressed more concern relating to
participation in large-scale, centralized research data re-
positories as well as threats of public institutions to consti-
tutional rights. Several studies conducted in Europe and in
the United States have confirmed such differences be-
tween participants and non-participants in terms of atti-
tudes towards risks and levels of trust, especially in
relation to genetic research [19, 23, 26, 32, 45–47].
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Our findings showed that intrapersonal differences
might exist between participants and non-participants
relating to their considerations on trust in society, and
in data repositories, as well as their perceptions about
society and research. These findings therefore provide
some support for significance of the relationship be-
tween trust and willingness to participate in research
that is well-established [18, 19, 23, 26, 45–47]. Although
a lack of trust is associated with high levels of concern
and low levels of awareness of current research and
data-sharing or data-linking practices [18, 19, 47, 48],
our findings indicate that simply increasing the provision
of information on data management or biobanking
might indeed not be enough [18].
Specifically, our findings show that a lack of engagement
in health research practices and inadequate communica-
tion of information do not fully explain non-participation
in biobanking, as perceptions about society and research
appeared to vary between participants and non-
participants. Recent quantitative studies conducted on in-
dividuals unwilling to contribute to biobanks confirmed
that their willingness to participate depended on their per-
ceptions and interest or familiarity in biobanking [18, 28].
Moreover, the findings of a pan-European quantitative
study and of a systematic review revealed that a preference
for broad or narrow informed consent depended on atti-
tudes towards biobanking research, such as benefits, con-
cerns, and information needs [19, 48]. These diverse
perceptions of benefits and risks are not confined to po-
tential participants. A recent systematic review confirmed
that there were marked variations in the perceptions of
members of expert groups and organizations regarding
pertinent ethical principles and regulatory norms govern-
ing the sharing of international health research data [49].
The formulation of objective criteria for the regulation and
the use of personal data is therefore essential in biomedical
research and for large-scale, centralized data repositories to
counter prejudices based on misunderstandings of risks and
benefits of biobanking. In other words, the focus of regula-
tion and use of personal data should be on enhancing trust-
worthiness of data repositories to provide objective
information about the biobanking context and addressing
concerns of participation and non-participation [50]. This is
the reason why criteria relating to organizations’ trustworthi-
ness need to be ingrained within current regulatory and in-
formed consent procedures and implemented more widely,
especially in the areas of learning health systems and person-
alized medicine that entail continuously changing data [50].
For example, a study conducted in Finland revealed that the
contexts in which donations were made to a blood bank for
patients or to biobanking could trigger different concerns
and attitudes [46]. The accounting for context becomes even
more key in the case of a large-scale, centralized data reposi-
tory because of the increasing morally ambiguous and
indirect consequences of participation in big data health re-
search for society and for participants [6, 51]. For example,
debates about insights in genetic test results and providing
feedback to individuals and their families about the genetic
risks are ongoing, given differing views on the ‘soft’ impacts
of genetic risks considered as a good practice [52, 53]. An ef-
fective regulatory framework should clearly stipulate the re-
sponsibilities of data repositories in relation to health
research while outlining the implications of participation and
non-participation. The findings of several European studies
confirm that the trustworthiness of the biobank and of the
biobanking context critically influence individuals’ decisions
to contribute their personal data [19, 32, 46, 48].
A practical implication that follows from a more nu-
anced understanding of the motives behind participation
and non-participation in large-scale, centralized data re-
positories relates to the need to acknowledge the im-
portant influence of intrapersonal factors, such as values,
trust in society, and interest. The adoption of a more
personalized approach in relation to potential partici-
pants could be facilitated through the development of
new models for communicating information and recruit-
ing participants for health research [54, 55]. A limited
focus on facts and consent within the prevailing general-
ized information and communication procedures leads
to the oversimplification of researcher–participant inter-
actions [8, 52] that does not address the need for more
layered and informative interactions in the contempor-
ary context of data collection and research. Our findings
revealed that issues of individual or societal benefits and
risks importantly influenced the respective decisions of
ex-participants and non-participants to withdraw or not
to participate at all. The findings of a recent systematic
review of similar studies showed that the public wel-
comes information about current research and data-
sharing practices [48]. Therefore, training programmes
developed for personnel who recruit individuals to con-
tribute to large-scale, centralized data repositories along
with the provision of a comprehensive explanation of
current practices and potential future implications of
participation to participants and non-participants are
important future tasks.
A notable strength of the present study lies in its in-
depth investigation of motives for (non-)participation.
Moreover, by including participants, non-participants,
and ex-participants in our study, we have been able to
provide a broad overview of the motives for (non-) par-
ticipation in large-scale, centralized health research data
repositories. However, this study also has some limita-
tions. Firstly, the samples, especially of ex-participants,
were relatively small. Consequently, some important mo-
tives for ending participation may have been missed des-
pite the samples’ heterogeneity. For example, it is likely
our study lacks the voices of ex-participants and non-
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participants not consenting due to limited time available
or a strong aversion of scientific research. Secondly, we
only investigated (non-)participation pertaining to a large-
scale, centralized data repository focusing on health re-
search. Therefore, our findings and conclusions are bound
to the specific context of health research. Their applicabil-
ity to other settings, such as sustainability research or con-
sumer services, requires further investigation.
Conclusions
In conclusion, we investigated and compared the motives
underlying participation, non-participation, and with-
drawal of participation in the context of a large-scale, cen-
tralized population-based biobank in the Netherlands.
Our findings revealed that motives for (non-) participation
are complex and that intrapersonal characteristics may be
important influencing factors. Acknowledgement of this
complexity and the pursuit of personalized approaches re-
lating to recruitment and information communication
procedures, along with effective regulatory frameworks,
could strengthen collaborative research and healthcare
initiatives.
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